RT Journal Article
SR Electronic
T1 Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.27.21264163
DO 10.1101/2021.09.27.21264163
A1 van Gils, Marit J.
A1 Ayesha Lavell, A. H.
A1 van der Straten, Karlijn
A1 Appelman, Brent
A1 Bontjer, Ilja
A1 Poniman, Meliawati
A1 Burger, Judith A.
A1 Oomen, Melissa
A1 Bouhuijs, Joey H.
A1 van Vught, Lonneke A.
A1 Slim, Marleen A.
A1 Schinkel, Michiel
A1 Wynberg, Elke
A1 van Willigen, Hugo D.G.
A1 Grobben, Marloes
A1 Tejjani, Khadija
A1 van Rijswijk, Jacqueline
A1 Snitselaar, Jonne L.
A1 Caniels, Tom G.
A1 ,
A1 Vlaar, Alexander P. J.
A1 Prins, Maria
A1 de Jong, Menno D.
A1 de Bree, Godelieve J.
A1 Sikkens, Jonne J.
A1 Bomers, Marije K.
A1 Sanders, Rogier W.
YR 2022
UL http://medrxiv.org/content/early/2022/03/25/2021.09.27.21264163.abstract
AB Background Emerging and future SARS-CoV-2 variants may jeopardize the effectiveness of vaccination campaigns. Therefore, it is important to know how the different vaccines perform against diverse SARS-CoV-2 variants.Methods In a prospective cohort of 165 SARS-CoV-2 naive health care workers, vaccinated with either one of four vaccines (BNT162b2, mRNA-1273, AZD1222 or Ad26.COV2.S), we performed a head-to-head comparison of the ability of sera to recognize and neutralize SARS-CoV-2 variants of concern (VOCs; Alpha, Beta, Gamma, Delta and Omicron). Repeated serum sampling was performed 5 times during a year (from January 2021 till January 2022), including before and after booster vaccination with BNT162b2.Findings Four weeks after completing the initial vaccination series, SARS-CoV-2 wild-type neutralizing antibody titers were highest in recipients of BNT162b2 and mRNA-1273 (geometric mean titers (GMT) of 197 [95% CI 149-260] and 313 [95% CI 218-448], respectively), and substantially lower in those vaccinated with the adenovirus vector-based vaccines AZD1222 and Ad26.COV2.S (GMT of 26 [95% CI 18-37] and 14 [95% CI 8-25] IU/ml, respectively). These findings were robust for adjustment to age and sex. VOCs neutralization was reduced in all vaccine groups, with the largest (9- to 80-fold) reduction in neutralization observed against the Omicron variant. The booster BNT162b2 vaccination increased neutralizing antibody titers for all groups with substantial improvement against the VOCs including the Omicron variant. Study limitations include the lack of cellular immunity data.Conclusions Overall, this study shows that the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after initial vaccination and after booster vaccination.Competing Interest StatementAmsterdam UMC filed a patent application on SARS-CoV-2 monoclonal antibodies including the ones used in this manuscript.Funding Statementthe Netherlands Organization for Scientific Research (NWO) ZonMw (no. 10430022010023 no. 10150062010002 no. 91818627)the Bill & Melinda Gates Foundation (no. INV-002022 no. INV008818 no. INV-024617)the Amsterdam UMC through the AMC Fellowship and the Corona Research Fundthe European Unions Horizon 2020 program (no. 101003589).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The S3 study, the COSCA study and the RECoVERED study were approved by the medical ethical review board of the Amsterdam University Medical Centers (NL73478.029.20, NL73281.018.20 and NL73759.018.20, respectively). All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or supplementary materials. Reagents used in this study are available upon reasonable request under an MTA with Amsterdam UMC.